ERBB2 and breast carcinoma: Of the factors affected by ITH in breast cancer, HER2 heterogeneity can be easily evaluated in breast cancer and can be matched with the response to HER2-targeted therapy, and thus has been the subject of many investigations including one by our group [31-33].